Imaging of receptors in clinical neurosciences

Acta Neurologica Belgica

Volumn 97, Issue 3, 1997, Pages 200-205

  Korf, Jakob ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Brain; Dopamine; Extrapyramidal symptoms; Inflammation; Neurotransmitter; Receptors; Shizophrenia

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR;

ALZHEIMER DISEASE; BRAIN; CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEGENERATIVE DISEASE; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; HUMAN; MENTAL DISEASE; METABOLISM; REVIEW; SCHIZOPHRENIA; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BRAIN; DOPAMINE; HUMANS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; RECEPTORS, DOPAMINE D2; RECEPTORS, NEUROTRANSMITTER; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031228372     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. AISEN P. S., DAVIS K. L. Inflammatory mechanisms in Alzheimer's disease : implications for therapy. Am J Psychiatry, 1994, 151 : 1105-1113.
2. 3HGBR-12935 in Alzheimer's disease. Europ Neurol, 1990, 36 : 181-185.
3. BARON J. C., MARTINOT J. L., BOULANGER J. P., POIRIR M. F., BLIN J. et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptics treatment : correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology, 1989, 99 : 463-469.
4. BONDAREFF W., MOUNTJOY C. Q., ROTH M. Selective loss of neurons of origin of adrenergic projection to cerebral cortex (n. locuscoeruleus) in senile dementia. Lancet, 1981, 1 : 783-784.
5. CLARK W. M., COULL B. M., BRILEY D. P., MAINOLFI E., ROTHLEIN R. Circulating intercellular adhesion molecule-1 levels and neutrophil adhesion in stroke. J Neuroimmunol, 1993, 44 : 123-5.
6. 2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy resistant schizophrenic patients. Biol Psychiatry, 1991, 29 : 629-634.
7. 1-dopamine receptor abnormalities in frontal cortex points to a functional alternation of cortical cell membranes in Alzheimer's disease. Arch Neurol, 1990, 47 : 761-764.
8. DEWAR D., CHALMERS D. T., GRAHAM D. I., MCCULLOCH J. Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease : an autoradiographic study of the hippocampus. Brain Res, 1991, 553 : 58-64.
9. EIKELENBOOM P., ZHAN S. S., VAN GOOL W. A., ALLSOP D. Inflammatory mechanism in Alzheimer's disease. Trends Pharmacol Sci, 1994, 15 : 447-450
10. ELSINGA P. H., Vos M. G., VAN WAARDE A., BRAKER A. H., DE GROOT T. J. (S,S)- and (S,R)-1'-18F fluorocarazolol, ligands for the visualization of pulmonary β-adrenergic receptors with PET. Nucl Med Biol, 1996, 23 : 159-167.
11. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry, 1988, 45 : 71-76.
12. 2 dopamine receptor occupancy treated with classical neuroleptics and clozapine. Arch Gen Psychiatry, 1992, 49 : 538-544.
13. 2-dopamine receptor blockade both induces akathisia in humans - a PET study with 11CSCH 23390 and 11Craclopride. Psychopharmacology, 1992, 107 : 23-29.
14. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 1990, 250 : 1429-1432.
15. HEINEL L. A., RUBIN S., ROSENWASSER R. H., VASTHARE U. S., TUMA R. F. Leukocyte involvement in cerebral infarct generation after ischemia and reperfusion. Brain Res Bull. 1994, 34 : 137-141.
16. ITAGAKI S., MCGEER P. L., AKIYAMA H. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci Lett, 1988, 91 : 259-264.
17. JAARSMA D., SEBENS J. B., KORF J. Reduction of A1-receptors in the perforant pathway terminal zone in Alzheimer hippocampus. Neurosci Lett, 1991, 121 : 111-114.
18. JAARSMA D., VEENMA-VAN DER DUIN L., KORF J. N-Acetylaspartate and N-acetylaspartyglutamate levels in Alzheimer's disease post mortem brain tissue. J Neurol Sci, 1994, 127 : 2230-2233.
19. JANDERS S., KRAEMER M., SCHROETER M., WITTE O. W., STOLL G. Lymphocyte infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex. J Cerebr Blood Flow Metab, 1995, 15 : 42-51.
20. JANSEN K. R., FAULL R. L. M., STOREY P., LESLIE R. A. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. Brain Res, 1993, 623 : 299-302.
21. JOYCE J. N., LEXOW N., KIM S. J., ARTYMYSHYN R., SENZON S. et al. Distribution of Beta-adrenergic receptor subtypes in human post-mortem brain : alterations in limbic regions of schizophrenics. Synapse, 1992, 10 : 228-246.
22. 2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transmission, 1991, 86: 163-173.
23. KORF J., COPPENS H. J., LOUWERENS J. W. Receptorblokkade bij antipsychotische medicatie. In : "Schizofrenie : Onderzoek en implicaties voor de behandeling." Dingemans P.M.A.J., Van den Bosch R.J., Kahn R.S., Schene A.H. eds., Houten, Bohn Stafleu Van Loghum, 1995, 122-133.
24. KORF J., KORF-VAN DER VEEN A. Farmacologische keuzecriteria voor antispychotica. In : "Praktische keuzecriteria voor psychofarmaca. Antipsychotica, Antidepressiva, Anxiolytica, Hypnotica." Hoes M.J.A.J.M., Nijdam S.J., Hekster Y.A. eds., Alphen aan den Rijn, Van Zuiden Communications, 1995, 20-29.
25. KORF J. Dopamine hypothese bij schizofrenie. In : "Leerboek Schizofrenie, een neurobiologische benadering." Den Boer J.A., Van den Bosch R.J. eds., Utrecht, De Tijdstroom 1996, 128-142.
26. LOUWERENS J. W., BUDDING' J. A., ZIJLSTRA S., PRUIM J., KORF J. et al. Dopamine (D2)-receptor occupancy in clozapine-treated patients as measured by positron emission tomography using 18FESP. In : "New generation of antipsychotic drugs : Novel mechanisms of action." Brunello N., Mendlewicz J., Racagni G. eds., Int. Acad. Biomed. Res. Basel, Karger, 1993, 4 : 130-135.
27. 2 and serotonin 2 receptor occupation by typical antipsychotic drugs in vivo. Pharmacol Exp Therapeutics, 1993, 265 : 498-508.
28. MCGEER P. L., ROGERS J., MCGEER E. G. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer. Disease Ass Disord, 1994, 8 : 149-158.
29. MCGEER P. L., MCGEER E. G. The inflammatory response system of brain : Implications for therapy of Alzheimer and other neurodegeneratives diseases. Brain Res Reviews, 1995, 21 : 195-218.
30. MIDDLEMISS D. N., PALMER A. M., EDEL N., BOWEN D. M. Binding of the novel sertonin agonist 8-Hydroxy-2-(Di-n-Propylamino) Tetralin in normal and Alzheimer brain. J Neurochem, 1986, 46: 993-996.
31. 3HPK 11195 binding in rat cerebral cortex following a local ischaemic lesion. J Cerebral Blood Flow Metabolism, 1991, 11 : 314-322.
32. NIETO-SAMPEDRO M., MORA F. Active microglia, sick astroglia and Alzheimer type dementias. Neuro Report, 1994, 5 : 375-380.
33. NORDBERG A. Neuroreceptor changes in Alzheimer Disease. Cerebrovasc Brain Metab Rev, 1992, 4 : 303-328.
34. NORDSTRÖM A.-L., FARDE L., HALLDIN C. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology, 1993, 110 : 365-367.
35. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology, 1993, 110 : 265-272.
36. OOSTERINK B. J., JANSEN H. M. L., PAANS A. M. J., WILLEMSEN A. T. M., HEW J. M. et al. Cobalt-55 positron emission tomography in senile dementia : a pilot study. J Cereb Blood Flow Metab, 1995, 15S1 : S794.
37. PASCUAL J., GRIJALBA B., GARCIA-SEVILLA J. A., ZARRANZ J. J., PAZOS A. Loss of high-affinity 2-adrenoceptors in Alzheimer's disease : an autoradiographic study in frontal cortex and hippocampus. Neurosci Lett, 1992, 142 : 36-40.
38. PERRY V. H., ANDERSSON P. B., GORDON S. Macrophages and inflammation in the central nervous system. Trends Neuro Sci, 1993, 16 : 268-273.
39. 11C]WAY-100635. Med Chem Res, 1994, 5 : 208-227.
40. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet, 1992, 340 : 199-202.
41. ROGERS J., KIRBY L. C., HEMPELMAN S. R., BERRY D. L., MCGEER P. L. et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology, 1993, 43 : 1609-1611.
42. SAWLE G. V. Imaging the head : functional imaging. J Neurol Neurosurg Psychiatry, 1995, 58 : 132-144.
43. SCHROETER M., JANDER S., WITTE O. W., STOLL G. Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. J Neuroimmunol ,1994, 55 : 195-203.
44. SEEMAN P., NIZNIK H. B., GUAN H. C. Elevation of dopamine D2 receptors in schzophrenia is underestimated by radioactive raclopride. Arch Gen Psychiatry. 1990, 47 : 1170-1172.
45. SKALIT F., SREDUI B., BRODIE C., KOTT E., HUBERMAN M. T-lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. Clin Immunol Immunopath, 1995, 75 : 246-250.
46. SWART J. A., KORF J. In vivo dopamine receptor assessment for clinical studies using positron emission tomography. Biochem Pharmacol, 1987, 36 : 2241-2250.
47. 2 receptors by irreversible tracerbinding in the living human brain : the model-dependent correctiom of metabolites. J Cerebr Blood Flow Metabol, 1989, 9 : 906-913.
48. SWART J. A. A., VANDER WERF J. F., WIEGMAN T., PAANS A. M. J., VAALBURG W. et al. In vivo binding of spiperon and N-mrthyl spiperon to dopaminergic and serotonergic sites in the rat brainmultiple modelling and implications for PET scanning. Cerebral Blood Flow Metabol, 1990, 10 : 297-306.
49. TALAMINI L. M., LOUWERENS J. W., SLOOFF C. J., KORF J. PET versus postmortem studies in schizophrenia research : significance for the pathogenesis and pharmacotherapy. In : "Advances in the neurobiology of schizophrenia." Den Boer J.A., Westenberg H.G.M., Van Praag H.M. eds., Chichester, John Wiley & Sons, 1994, 157-187.
50. 2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain, 1995, 118 : 689-696.
51. VISSER G. M., VAN WAARDE A., MEDEMA J., VAALBURG W. Selective 5-HT1A receptor ligands for PET : A comparative study of [11C]WAY-100635 and [11C]ORG-13502. J Label Comp Radiopharm, 1995, 37 : 280-282.
52. VOGT B. A., CRINO P. B., VOLICER L. Laminar alterations in γ-aminobutyricacid, muscarinic, and β-adrenoceptor and neuron degeneration in cingulate cortex in Alzheimer's disease. J Neurochem, 1991, 57 : 282-290.
53. WANG P-Y., KAO C.-H., MUI M.-Y, WANG S.-J. Leucocyte infiltration in acute hemispheric ischemic stroke. Stroke, 1993, 24 : 236-240.
54. WEKERLE H. Lymphocyte traffic to the brain. In : "Blood Brain Barrier". Pardridge W.A. ed., New York, Raven Press, 1993, 67-81.
55. WOLKIN A., BAROUCHE F., WOLF A. P., ROTROSEN J., FOWLER J. S. et al. Dopamine blockade and clinical response : evidence for two biological subgroups of schizophrenia. Am J Psychiatry, 1989, 46 : 905-908.
56. 2-dopamine receptor occupancy with positron emission tomography in long term medicated schizophrenic patients. In : "Brain Dopaminergic Systems : Imaging with Positron Tomography." Baron J.C., Comar D., Martinot J.L., Mazoyer B. eds., Dordrecht, Kluwer Academic Publishers, 1991, 181-190.
57. ZLJLSTRA S., VAN DER WORP H., WIEGMAN T., VISSER G. M., KORF J. et al. Synthesis and in vivo distribution in the rat of a dopamine agonist : N-([11C]methyl)norapomorphine. Nucl Med Biol, 1993, 20 : 7-12.